THE IMPACT OF GLEASON SCORE FROM THE BIOPSY AND FROM THE RADICAL PROSTATECTOMY ON THE BIOCHEMICAL PROGRESSION-FREE SURVIVAL

Abstract

Introduction: Prostate cancer (PCa) in stages T1 and T2 can be treated either with radical prostatectomy (RP) or with radiotherapy. But in the clinical trials, the survival probability after RP is related to the Gleason score (GS) from the operation and the survival probability after radiotherapy - to the GS from the biopsy. Both GSs often do not coincide. Objective: To study the connection between biopsy/prostatectomy-GS of a homogeneous group of patients, all treated only with RP, and the biochemical progression-free survival (BPFS) of those patients. Methods: The patients available for analysis were 111. All underwent RP (either open or laparoscopic) in our institution. Information about the GSs and the BPFS was collected and analyzed using IBM SPSS version 23. Parametric and non-parametric statistical methods were used. Results: Time to biochemical progression is shorter for patients with biopsy- and prostatectomy- GS≥ 7 compared with biopsy- and prostatectomy-GS < 7 patients. Discussion: With this study, we show that both GSs have a similar implication on the BPFS, with prostatectomy-GS giving slightly better accuracy than the biopsy-GS in predicting survival. Conclusion: Both GSs are comparable and can be used when discussing the survival probabilities of the patient and choosing the treatment options.

Keywords

• prostate cancer
• gleason score
• biochemical progression-free survival